Oncoclínicas do Brasil Serviços Médicos (ONCO3) Q4 2024 earnings summary

Executive summary

• 2024 was a year of transition, marked by a focus on building a healthier foundation, organic net debt reduction of R$112.3 million in Q4, and a shift to positive cash flow generation.

• Gross revenue reached R$6.8 billion in 2024, up 13.5% year-over-year, driven by organic growth, acquisitions, and new partnerships.

• Despite revenue growth, a net loss of R$717.4 million was posted in 2024, mainly due to a non-cash, non-recurring impairment charge of R$796.1 million and higher operating expenses.

• A R$1.5 billion capital increase improved liquidity and capital structure, supporting future growth cycles.

• The company was recognized as #1 Overall Best CEO, CFO, and IR Officer in the 2024 Latin America Executive Team awards.

Financial highlights

• Gross revenue in Q4 2024 was R$1.7 billion, up 9.2% year-over-year; annual gross revenue was R$6.8 billion, up 13.5%.

• Net revenue in 2024 was R$6.23 billion, up 13.4% year-over-year.

• Adjusted EBITDA for Q4 2024 was R$272.1 million (margin 17.4%); full-year adjusted EBITDA was R$1,152.7 million (margin 18.5%).

• Net loss in 2024 was R$717.4 million, mainly due to impairment; adjusted net income ex-LTIP and impairment was R$42.6 million.

• Free cash flow was neutral or positive for the second consecutive quarter; net debt reduced by R$112.3 million in Q4 2024.

Outlook and guidance

• Management expects margin recovery and deleveraging in 2025 as restructuring costs subside and new commercial agreements ramp up.

• Anticipated reacceleration of top-line growth in 2025, driven by new partnerships, expansion projects, and increased client base.

• Commercial strategy prioritizes cash flow generation, cost discipline, and working capital improvements.